PGLYRP1 and heart failure: Signs of heart failure and LVEF decrease to <40% was recorded in 4 patients with elevated mRNA and protein expression of PGLYRP1, CAMP, MMP9 and CEACAM8 at baseline and after the initial chemotherapy dose.